Fosamax Osteonecrosis of the Jaw Settlement: Statute of Limitations for Fosamax in California

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: From General Health to Occupational Exposure

For decades, general health and science communication has served as the foundation for public understanding of medication safety and long-term therapeutic outcomes. This legacy context established frameworks for evaluating drug benefits alongside potential adverse effects, particularly for treatments prescribed across large populations. Within this broad informational landscape, the bisphosphonate class of medications—including Fosamax—emerged as a standard intervention for bone density management, with routine clinical guidance emphasizing skeletal health maintenance. As public health awareness matured, attention gradually shifted from generalized medication profiles toward specific exposure scenarios encountered in occupational settings. The transition from patient-centered health information to workplace hazard recognition becomes particularly relevant when considering prolonged chemical contact during manufacturing, handling, or distribution processes. Workers in pharmaceutical production environments may face repeated dermal or inhalational exposure to active pharmaceutical ingredients, including bisphosphonates, at concentrations exceeding those in prescribed doses. This pivot from consumer health education to occupational exposure concern requires careful consideration of how legacy health frameworks inform current risk assessment practices. The established precedent of monitoring medication effects in general populations now extends to evaluating potential consequences of sustained workplace contact.

Bridging to Fosamax and Osteonecrosis of the Jaw

Understanding the temporal relationship between exposure onset and manifestation of adverse outcomes—such as osteonecrosis of the jaw (ONJ)—becomes critical for determining appropriate legal and regulatory responses, including statute of limitations considerations in jurisdictions like California. Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Medical Evidence: Fosamax and ONJ Risk

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanism and Clinical Considerations

Mechanistically, bisphosphonate-related ONJ is linked to the drug's effects on bone remodeling. Bisphosphonates inhibit osteoclast activity, which can suppress normal bone turnover and repair processes. This suppression, combined with local factors such as infection or trauma, may lead to impaired healing and necrosis of the jawbone. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique structure and high remodeling rate may make it particularly susceptible to bisphosphonate-induced suppression of bone turnover. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms related to ONJ were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, post-marketing reports have identified ONJ as a potential adverse reaction. The safety of Fosamax 70 mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year study comparing once-weekly and daily dosing, and the overall safety and tolerability profiles were similar (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Context and Statute of Limitations in California

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4, 'Osteonecrosis of the Jaw,' which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This warning informs healthcare providers and patients about the potential risk, particularly in the context of dental procedures and other risk factors. For affected patients in California considering settlement-related considerations, the statute of limitations for filing a claim related to Fosamax and ONJ is a critical factor. The timeline between exposure to Fosamax and documented harm is variable, with symptom onset ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ may also develop after longer-term use, and the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should be aware that the statute of limitations in California for personal injury claims generally begins to run from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. Given the potential for delayed onset of ONJ, the discovery rule may apply, allowing the statute to start when the patient knew or should have known that the injury was caused by Fosamax. Legal consultation is recommended to determine individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in California?

In California, the statute of limitations for personal injury claims generally begins from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For ONJ, which may have delayed onset, the discovery rule may apply, allowing the statute to start when the patient knew or should have known that Fosamax caused the injury. Legal consultation is recommended for individual circumstances.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.